Skip to Content

Docetaxel Mylan

Active Substance: docetaxel, anhydrous
Common Name: docetaxel
ATC Code: L01CD02
Marketing Authorisation Holder: Mylan S.A.S.
Active Substance: docetaxel, anhydrous
Status: Withdrawn
Authorisation Date: 2012-01-31
Therapeutic Area: Carcinoma, Non-Small-Cell Lung Prostatic Neoplasms Head and Neck Neoplasms Adenocarcinoma Breast Neoplasms
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

Treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.

The marketing authorisation for Docetaxel Mylan has lapsed becasue it has not been marketed in the European Union in the three years following the granting of the authorisation.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.